SCHEMBL6340691

SCHEMBL6340691

S=C(NCc1ccc(Cl)cc1)c1cnc2sccc2c1S

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
POLB P06746 2/20 0.41
KDM4E B2RXH2 1/20 0.41
MAPT P10636 2/20 0.38
MAPK1 P28482 2/20 0.38
RECQL P46063 1/20 0.38
ALDH1A1 P00352 1/20 0.36
HTT P42858 1/20 0.36
SMN1; SMN2 Q16637 1/20 0.36
CYP2C9 P11712 3/20 0.35
CYP2C19 P33261 3/20 0.35
CYP1A2 P05177 2/20 0.35
CYP3A4 P08684 1/20 0.35
CYP2D6 P10635 1/20 0.35
MEN1 O00255 3/20 0.35
KMT2A Q03164 3/20 0.35
NR3C1 P04150 1/20 0.35
HPGD P15428 2/20 0.35
ALOX12 P18054 1/20 0.35
FFAR2 O15552 1/20 0.35
NPSR1 Q6W5P4 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6632903 0.86 NR3C1 (0.47) POLBKDM4EALDH1A1HTTSMN1; SMN2
SCHEMBL6340791 0.81 SMN1; SMN2 (0.35) MAPTMAPK1ALDH1A1SMN1; SMN2MEN1
SCHEMBL6339994 0.81 MAPT (0.37) MAPTMAPK1ALDH1A1SMN1; SMN2MEN1
SCHEMBL6347826 0.80 RXFP1 (0.36) MAPTMAPK1ALDH1A1MEN1KMT2A
SCHEMBL6339252 0.78 SMN1; SMN2 (0.34) MAPTMAPK1ALDH1A1SMN1; SMN2MEN1
SCHEMBL6340795 0.77 RXFP1 (0.34) MAPTCYP2C9CYP2C19CYP1A2HPGD
SCHEMBL6337982 0.76 SMN1; SMN2 (0.33) MAPTMAPK1ALDH1A1SMN1; SMN2MEN1
SCHEMBL6633898 0.75 RXFP1 (0.33) SMN1; SMN2
SCHEMBL6707960 0.75 EGLN1 (0.49) POLBKDM4EALDH1A1HTTSMN1; SMN2
SCHEMBL6336604 0.75 SMN1; SMN2 (0.32) MAPTMAPK1ALDH1A1SMN1; SMN2CYP2C9

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6924283-B2 4-thioxo-4,7-dihydro-thieno[2,3-b]pyridine-5-carbothioamides as antiviral agents PFIZER (US) 2005-08-02 US claimed
EP-1421088-A1 4-THIOXO-4,7-DIHYDRO-THIENO 2,3-B]PYRIDINE-5-CARBOTHIOAMIDES AS ANTIVIRAL AGENTS PHARMACIA & UPJOHN COMPANY (US) 2004-05-26 EP claimed
US-20030100536-A1 4-Thioxo-4,7-dihydro-thieno[2,3-b]pyridine-5-carbothioamides as antiviral agents PHARMACIA & UPJOHN COMPANY 2003-05-29 US claimed
WO-2003020730-A1 4-THIOXO-4,7-DIHYDRO-THIENO[2,3-B]PYRIDINE-5-CARBOTHIOAMIDES AS ANTIVIRAL AGENTS PHARMACIA & UPJOHN COMPANY (US) 2003-03-13 WO claimed
WO-2003020728-A1 4-THIOXO-4,7-DIHYDRO-THIENO[2,3-b]PYRIDINE-5-CARBOTHIOAMIDES AS ANTIVIRAL AGENTS PHARMACIA & UPJOHN COMPANY (US) 2003-03-13 WO claimed
US-6924283-B2 4-thioxo-4,7-dihydro-thieno[2,3-b]pyridine-5-carbothioamides as antiviral agents PFIZER (US) 2005-08-02 US disclosed
EP-1421088-A1 4-THIOXO-4,7-DIHYDRO-THIENO 2,3-B]PYRIDINE-5-CARBOTHIOAMIDES AS ANTIVIRAL AGENTS PHARMACIA & UPJOHN COMPANY (US) 2004-05-26 EP disclosed
US-20030100536-A1 4-Thioxo-4,7-dihydro-thieno[2,3-b]pyridine-5-carbothioamides as antiviral agents PHARMACIA & UPJOHN COMPANY 2003-05-29 US disclosed
WO-2003020730-A1 4-THIOXO-4,7-DIHYDRO-THIENO[2,3-B]PYRIDINE-5-CARBOTHIOAMIDES AS ANTIVIRAL AGENTS PHARMACIA & UPJOHN COMPANY (US) 2003-03-13 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030100536-A1 4-Thioxo-4,7-dihydro-thieno[2,3-b]pyridine-5-carbothioamides as antiviral agents TPMT, TK1, TYMP POLB 459/4885KDM4E 492/4885MAPT 4095/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.